Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study
- 57 Downloads
This population-based study aims to assess prognosis of prostate cancer diagnosed with prostate-specific antigen (PSA) levels <4 ng/ml in routine care.
Materials and methods
We compared prostate cancer patients with low PSA values (n=59) with other prostate cancer patients (n=1330) by logistic regression and the Cox model using data from the Geneva Cancer Registry.
Patients with low PSA values more frequently had early-stage and well differentiated tumours. Nevertheless, 35% presented with aggressive tumour characteristics or metastases. After adjustment for other prognostic factors, prostate cancer-specific mortality was similar for both groups (hazard ratio: 1.1; 95%CI: 0.6–2.2).
We conclude that cancer with low PSA values at diagnosis is not indolent.
KeywordsProstate cancer Prostate-specific antigen Tumour characteristics Survival Mortality
Unable to display preview. Download preview PDF.
- 1.American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. http://www.cancernetwork.com/journals/oncology/o0002e.htm#Early. Accessed 1 March 2006
- 10.Aus G, Robinson D, Rosell J et al (2005) Survival in prostate carcinoma — outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 103:943–951PubMedCrossRefGoogle Scholar
- 14.Stamey TA, Johnstone IM, McNeal JE et al (2002) Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 167:103–111PubMedCrossRefGoogle Scholar
- 24.World Health Organization (WHO) (1976) ICD-O International classification of diseases for oncology, 1st Edn. World Health Organization, GenevaGoogle Scholar
- 25.Sobin LH, Wittekind Ch (2002) TNM classification of malignant tumours, 6th Edn. UICC, New YorkGoogle Scholar
- 26.Greenwood M (1926) The natural duration of cancer, 33rd Edn. Her Majesty’s Stationary Office, LondonGoogle Scholar
- 34.Partin AW, Hanks GE, Klein EA et al (2002) Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Williston Park) 16:1024–1038, 1042Google Scholar